Proposal for tertiary prevention intervention for epithelial ovarian cancer in Chile: Implementation of a comprehensive monitoring and support model
DOI:
https://doi.org/10.52611/confluencia.2025.1350Keywords:
Epithelial ovarian cancer, Tertiary prevention, Psychosocial care, Quality of lifeAbstract
Introduction: Epithelial ovarian cancer is the gynecological cancer with the most lethality, late diagnosis, and high mortality. In Chile, the mortality rate is 5,3 per 100.000 women. The lack of effective strategies in primary and secondary prevention highlights the importance of tertiary prevention, which focuses on improving patients' quality of life after treatment. Objective: Implement a comprehensive follow-up and support model for women treated for epithelial ovarian cancer, including medical and psycho-emotional interventions to optimize rehabilitation. Methodology: A review of both indexed and gray literature was performed using databases like PubMed and Chilean Ministry of Health, focusing on research from the past decade regarding treatment, rehabilitation, and palliative care in epithelial ovarian cancer. Result: The main strategies include cytoreductive surgery, platinum-based chemotherapy, and therapies such as poli (ADP-ribosa) polimerasa inhibitors and Bevacizumab. Additionally, psychoeducational interventions and support groups have been shown to benefit mental health. In Chile, treatment is covered by the Explicit Health Guarantees, but there are no comprehensive rehabilitation programs. Discussion: Chile has not updated its treatment guidelines in over 10 years and lacks post-surgical rehabilitation strategies. A proposed program includes group support, mindfulness, and sexual health education. Conclusion: It is essential to implement a comprehensive approach that combines medical treatment with psycho-emotional rehabilitation centered on the condition of life of patients with epithelial ovarian cancer.
Downloads
References
Global Cancer Observatory. Estimated age-standardized incidence and mortality rates (World) in 2020, Chile, females, all ages [Internet]. Ginebra: Globocan WHO; 2020 [citado el 11 de abril 2025]. Disponible en: https://gco.iarc.who.int/media/globocan/factsheets/populations/152-chile-fact-sheet.pdf
Ministerio de Salud de Chile. Resumen ejecutivo. Guía de práctica clínica Cáncer de Ovario Epitelial – 2018 [Internet]. Santiago: Subsecretaría de Salud Pública; 2018 [citado el 11 de abril 2025]. Disponible en: https://docs.bvsalud.org/biblioref/2021/04/1177418/08-re_gpc-ovario-epitelial_2018v3.pdf
World Health Organization. WHO Mortality Database. Ovary cancer [Internet]. Ginebra: WHO; 2025 [citado 11 de abril 2025]. Disponible en: https://platform.who.int/mortality/themes/theme-details/topics/indicator-groups/indicator-group-details/MDB/ovary-cancer
Instituto Nacional de Estadísticas. Estimaciones y proyecciones de la población de Chile 1992-2050. Total país. Síntesis de Resultados [Internet]. Santiago: INE; 2018 [citado el 11 de abril 2025]. Disponible en: http://www.censo2017.cl/descargas/proyecciones/sintesis-estimaciones-y-proyecciones-de-la-poblacion-chile-1992-2050.pdf
Jammal MP, Lima CA, Murta EFC, Nomelini RS. Is Ovarian Cancer Prevention Currently Still a recommendation of Our Grandparents? Rev Bras Ginecol Obstet [Internet]. 2017 [citado el 27 de octubre 2023];39(12):676-85. Disponible en: https://doi.org/10.1055/s-0037-1608867
Eoh KJ, Park EY, Chang YJ, Ha HI, Hong J, Huang D, et al. The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis. Gynecol Oncol [Internet]. 2021 [citado el 11 de noviembre 2023];163(1):142-7. Disponible en: https://doi.org/10.1016/j.ygyno.2021.07.028
Ramos MCA, Folgueira MAAK, Maistro S, Campolina AG, Soárez PC, Bock GH, et al. Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation. Rev Saude Publica [Internet]. 2018 [citado el 22 de abril 2025];52:94. Disponible en: https://doi.org/10.11606/s1518-8787.2018052000643
Filis P, Mauri D, Markozannes G, Tolia M, Filis N, Tsilidis K. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. ESMO Open [Internet]. 2022 [citado el 4 de diciembre 2023];7(5):100586. Disponible en: https://doi.org/10.1016/j.esmoop.2022.100586
Kim SI, Kim J-W. Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer. ESMO Open [Internet]. 2021 [citado el 4 de diciembre 2023];6(3):100149. Disponible en: http://dx.doi.org/10.1016/j.esmoop.2021.100149
Mao CL, Seow KM, Chen KH. The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects. Int J Mol Sci [Internet]. 2022 [citado el 27 de octubre 2023];23(13):6911. Disponible en: https://doi.org/10.3390/ijms23136911
Alvarez Secord A, O'Malley DM, Sood AK, Westin SN, Liu JF. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. Gynecol Oncol [Internet]. 2021 [citado el 27 de octubre 2023];162(2):482-95. Disponible en: https://doi.org/10.1016/j.ygyno.2021.05.018
Tattersall A, Ryan N, Wiggans AJ, Rogozinska E, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev [Internet]. 2022 [citado el 27 de octubre 2023];2(2):CD007929. Disponible en: https://doi.org/10.1002/14651858.cd007929.pub4
Institute for Health Metrics and Evaluation. GBD Compare. Global, Both sexes, Alla ges, 2021, DALYs [Internet]. Washington: IHME; 2021 [citado el 5 de diciembre 2023]. Disponible en: https://vizhub.healthdata.org/gbd-compare/
Hu S, Baraghoshi D, Chang CP, Rowe K, Snyder J, Deshmukh V, et al. Mental health disorders among ovarian cancer survivors in a population-based cohort. Cancer Med [Internet]. 2023 [citado el 5 de diciembre 2023];12(2):1801-12. Disponible en: http://dx.doi.org/10.1002/cam4.4976
Gallardo-Rincón D, Bahena-González A, Álvarez-Rosa RM, Gómez-García E, Cortés-Esteban P, Villalobos-Valencia R, et al. Recomendaciones sobre el tratamiento farmacológico del cáncer de ovario epitelial en México. Gac Med Mex [Internet]. 2021 [citado el 5 de diciembre 2023];157(spe1):1-11. Disponible en: http://dx.doi.org/10.24875/gmm.m21000569
Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin [Internet]. 2019 [citado el 27 de octubre 2023];69(4):280-304. Disponible en: https://doi.org/10.3322/caac.21559
Delgado-Ortega L, Ginés Rubió J, Garcías de España MDC, Carcedo D, Cordero Puentes L, Moya de Alarcón C. Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain. Farm Hosp [Internet]. 2018 [citado el 27 de octubre 2023];42(3):95-102. Disponible en: https://doi.org/10.7399/fh.10904
Ministerio de Salud de Chile. Plan Nacional del Cáncer 2018-2028 [Internet]. Santiago: MINSAL; 2018 [citado el 22 de abril 2025]. Disponible en: https://cdn.digital.gob.cl/filer_public/d3/0a/d30a1f5e-53d9-4a31-a4fe-e90d8d9a2348/documento_plan_nacional_de_cancer.pdf
Gobierno de Chile. Cáncer de Ovario Epitelial [Internet]. Santiago: Fonasa; 2025 [citado el 4 de diciembre 2023]. Disponible en: https://nuevo.fonasa.gob.cl/coberturas-de-salud/cancer-de-ovario-epitelial/
Ministerio de Salud de Chile. Guía Clínica AUGE: Cáncer de Ovario Epitelial [Internet]. Santiago: MINSAL; 2013 [citado el 22 de abril 2025]. Disponible en: http://www.repositoriodigital.minsal.cl/bitstream/handle/2015/1126/2411.pdf?sequence=1&isAllowed=y
Ministerio de Salud de Chile. Guía Rápida GES. 4. Alivio del Dolor y Cuidados Paliativos por Cáncer Avanzado [Internet]. Santiago: Departamento GES de Redes Asistenciales; 2016 [citado el 27 de octubre 2023]. Disponible en: https://www.saludtarapaca.gob.cl/wp-content/uploads/2023/12/4-Alivio-del-Dolor-y-Cuidados-Paliativos.pdf
Bober SL, Recklitis CJ, Michaud AL, Wright AA. Improvement in sexual function after ovarian cancer: Effects of sexual therapy and rehabilitation after treatment for ovarian cancer. Cancer [Internet]. 2018 [citado el 27 de octubre 2023];124(1):176-82. Disponible en: https://doi.org/10.1002/cncr.30976
Ben-Arye E, Lavie O, Heyl W, Ramondetta L, Berman T, Samuels N. Integrative Medicine for Ovarian Cancer. Curr Oncol Rep [Internet]. 2023 [citado el 27 de octubre 2023];25(6):559-68. Disponible en: https://doi.org/10.1007/s11912-023-01359-8
Palao Á, Rodríguez B, Priede A, Maeso A, Arranz H. Cambios psicológicos e intervenciones basadas en mindfulness para los supervivientes de un cáncer. Psicooncología [Internet]. 2011 [citado el 27 de octubre 2023];8(1):7-20. Disponible en: https://doi.org/10.5209/rev_PSIC.2011.v8.n1.1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Revista Confluencia
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
